News //

New Look. New Portfolio. New Opportunities.

Outsmart molecular complexity - OncoDNA group
Following its acquisition by OncoDNA, IntegraGen has been given a brand new look and is ready to take on new projects in the fields of cancer and genetic diseases.

Since the successful takeover in November 2020, IntegraGen has been working hand in hand with OncoDNA (…)  » 

News //

New perspectives for the diagnosis and treatment of cisplatin-resistant pediatric liver cancers

Duchenne Muscular Dystrophy
Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer

IntegraGen is delighted to share this new publication on tumor plasticity and cisplatin resistance in pediatric liver cancers. Sequencing services (WES, RNA-seq, snRNA-seq, RRBS) and expertise support, particularly for single nuclei RNA-seq experiment, (…)  » 

News //

Technical Brief: Low-Pass Whole Genome Sequencing – Getting more from less

LP-WGS analysis of liquid biopsies (ctDNA) for oncology applications Background

Analysis of circulating tumor DNA (ctDNA) offers great opportunities for cancer research and patient care. There are multiple applications and benefits associated with studying ctDNA including the ability to identify tumor heterogeneity and the detection of somatic mutations unidentified following (…)  »